Scanlan Jacqueline
Known title: Executive VP & Chief HROCIK: 0001713517
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
UBS Cuts Axalta Price Target to $36, Maintains Neutral Rating. UBS lowered its price target for Axalta to $36 while keeping a neutral stance. The company also announced the date for its third-quarter 2026 earnings call. These updates provide new context as Axalta trades near its 52-week low, with the stock currently sitting above a key support level.
Transaction History
| FMC | ▼ Sell | Tax Withholding | 5,137 | $49K | 9/28/2026 | View on chart |
| FMC | ▼ Sell | Tax Withholding | 1,404 | $21K | 2/23/2026 | View on chart |
| FMC | ▲ Buy | Grant | 42,232 | $0 | 2/19/2026 | View on chart |
| FMC | ▼ Sell | Open Market | 3,790 | $129K | 9/29/2025 | View on chart |
| FMC | ▼ Sell | Tax Withholding | 5,177 | $174K | 9/29/2025 | View on chart |
| FMC | ▼ Sell | Open Market | 1,510 | $57K | 8/18/2025 | View on chart |
| FMC | ▲ Buy | Grant | 9,084 | $0 | 2/21/2025 | View on chart |
| FMC | ▲ Buy | Grant | 583 | $0 | 2/18/2025 | View on chart |
| FMC | ▲ Buy | Grant | 28 | $0 | 2/18/2025 | View on chart |
| FMC | ▼ Sell | Open Market | 4,529 | $270K | 11/11/2024 | View on chart |
| FMC | ▼ Sell | Tax Withholding | 5,132 | $339K | 9/27/2024 | View on chart |
| FMC | ▲ Buy | Grant | 4,799 | $0 | 2/20/2024 | View on chart |
| FMC | ▲ Buy | Grant | 33,511 | $0 | 9/27/2023 | View on chart |
| AXTA | ▼ Sell | Open Market | 17,008 | $501K | 8/9/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 16,266 | — | 7/27/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 6,910 | $221K | 7/27/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 2,873 | — | 6/14/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,221 | $40K | 6/14/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 11,545 | — | 6/14/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 4,905 | $159K | 6/14/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 3,238 | — | 2/15/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,529 | $45K | 2/15/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 2,873 | — | 6/14/2022 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,221 | $30K | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
FMC Faces Multiple Analyst Downgrades and Price Target Cuts
Several analysts have lowered their outlook on FMC, cutting price targets to as low as $4 and $5. The stock fell 31% in recent trading, and some analysts warn the dividend could be at risk amid a pesticide price war. These moves reflect growing concerns about FMC's earnings prospects and market valuation.
FMC Faces Multiple Analyst Downgrades and Price Target Cuts. Several analysts have lowered their outlook on FMC, cutting price targets to as low as $4 and $5. The stock fell 31% in recent trading, and some analysts warn the dividend could be at risk amid a pesticide price war. These moves reflect growing concerns about FMC's earnings prospects and market valuation.